Suppr超能文献

骨髓中骨髓瘤的组织病理学。

The histopathology of myeloma in the bone marrow.

作者信息

Fujino Masahiko

出版信息

J Clin Exp Hematop. 2018;58(2):61-67. doi: 10.3960/jslrt.18014.

Abstract

Myeloma is characterized by the neoplastic proliferation of monoclonal plasma cells. A diagnosis of myeloma is based on the criteria proposed by the International Myeloma Working Group and the pathological findings.Myeloma cells are classified into four types: mature, immature, pleomorphic, and plasmablastic. There are three patterns in which myeloma infiltrates bone marrow - nodular, interstitial, and diffuse. Dutcher bodies are highly specific to neoplastic myeloma cells. On immunohistochemical staining, the specificity of CD138 is high for plasma cells. As a clear image is often not obtained from the immunohistochemical staining of the immunoglobulin light chain, in situ hybridization is recommended. Abnormal expression of CD56 is seen in 70-80% of cases by flow cytometry analysis. CD56 expression definitively indicates myeloma, suggesting its high diagnostic value. Evaluation of the infiltration pattern, monoclonality, and abnormal antigen expression of plasma cells is more important than the plasmocytic ratio to determine whether a case is reactive or neoplastic.Multiple gene abnormalities function in the onset and progression of myeloma. In our department, we analyze CCND1, FGFR3, MAF, and del (17p13) by FISH for all myeloma cases. None of the cases with genetic abnormalities were recognized by G-banding. Therefore, FISH is more effective than G-banding for the evaluation of genetic abnormalities in myeloma.

摘要

骨髓瘤的特征是单克隆浆细胞的肿瘤性增殖。骨髓瘤的诊断基于国际骨髓瘤工作组提出的标准和病理检查结果。骨髓瘤细胞分为四种类型:成熟型、未成熟型、多形性和浆母细胞型。骨髓瘤浸润骨髓有三种模式——结节状、间质型和弥漫型。杜氏小体对肿瘤性骨髓瘤细胞具有高度特异性。在免疫组化染色中,CD138对浆细胞的特异性较高。由于免疫球蛋白轻链的免疫组化染色通常难以获得清晰图像,因此建议采用原位杂交。通过流式细胞术分析,70 - 80%的病例可见CD56异常表达。CD56表达明确提示骨髓瘤,表明其具有较高的诊断价值。评估浆细胞的浸润模式、单克隆性和异常抗原表达对于判断病例是反应性还是肿瘤性比浆细胞比例更为重要。多种基因异常在骨髓瘤的发生和发展中起作用。在我们科室,对所有骨髓瘤病例均采用荧光原位杂交(FISH)分析CCND1、FGFR3、MAF和del(17p13)。所有基因异常病例均未通过G显带识别。因此,在评估骨髓瘤的基因异常方面,FISH比G显带更有效。

相似文献

1
The histopathology of myeloma in the bone marrow.
J Clin Exp Hematop. 2018;58(2):61-67. doi: 10.3960/jslrt.18014.
3
Histopathology in the diagnosis of high-risk myelodysplastic syndromes.
J Clin Exp Hematop. 2018;58(2):51-60. doi: 10.3960/jslrt.18009.
4
Histomorphology of multiple myeloma on bone marrow biopsy.
Indian J Pathol Microbiol. 2004 Jul;47(3):359-63.
5
Plasma cell morphology in multiple myeloma and related disorders.
Morphologie. 2015 Jun;99(325):38-62. doi: 10.1016/j.morpho.2015.02.001. Epub 2015 Apr 18.
7
Myelodysplastic syndromes: preleukemic or early leukemic conditions?
Haematol Blood Transfus. 1990;33:3-7. doi: 10.1007/978-3-642-74643-7_1.
8
[Cytogenetic abnormalities and morphological changes of bone marrow in multiple myeloma: a pathological analysis of 151 cases].
Zhonghua Bing Li Xue Za Zhi. 2020 Nov 8;49(11):1136-1141. doi: 10.3760/cma.j.cn112151-20200306-00178.

引用本文的文献

1
Plasma Cell Leukemia With Spindle-Cell Morphology and CD22 Positivity on Flow Cytometry.
Cureus. 2025 May 3;17(5):e83402. doi: 10.7759/cureus.83402. eCollection 2025 May.
2
Neuroscience of cancer: Research progress and emerging of the field.
Ibrain. 2024 Aug 14;10(3):305-322. doi: 10.1002/ibra.12172. eCollection 2024 Fall.
4
Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma.
Pharmaceutics. 2023 Nov 25;15(12):2674. doi: 10.3390/pharmaceutics15122674.
5
Malignant Brain and Spinal Tumors Originating from Bone or Cartilage.
Adv Exp Med Biol. 2023;1405:477-506. doi: 10.1007/978-3-031-23705-8_18.
6
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
Cancer Lett. 2023 Aug 1;568:216284. doi: 10.1016/j.canlet.2023.216284. Epub 2023 Jun 24.
8
Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.
Skeletal Radiol. 2022 Jan;51(1):17-30. doi: 10.1007/s00256-021-03754-3. Epub 2021 Mar 9.
9
Rapidly Progressive Acute Liver Failure in Relapsed Multiple Myeloma.
Cureus. 2020 Dec 28;12(12):e12346. doi: 10.7759/cureus.12346.

本文引用的文献

1
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
2
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.
3
Myeloma cell morphology and morphometry in correlation with clinical stages and survival.
Diagn Cytopathol. 2013 Nov;41(11):947-54. doi: 10.1002/dc.22986. Epub 2013 Apr 3.
4
Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Int J Hematol. 2013 Mar;97(3):313-23. doi: 10.1007/s12185-013-1291-2. Epub 2013 Feb 28.
6
Molecular pathogenesis of multiple myeloma and its premalignant precursor.
J Clin Invest. 2012 Oct;122(10):3456-63. doi: 10.1172/JCI61188. Epub 2012 Oct 1.
8
Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Semin Hematol. 2011 Jan;48(1):4-12. doi: 10.1053/j.seminhematol.2010.11.003.
9
Immunophenotyping in multiple myeloma and related plasma cell disorders.
Best Pract Res Clin Haematol. 2010 Sep;23(3):433-51. doi: 10.1016/j.beha.2010.09.002.
10
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
Leukemia. 2009 Dec;23(12):2210-21. doi: 10.1038/leu.2009.174. Epub 2009 Oct 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验